US OptionsDetailed Quotes

BCDA240816C2500

Watchlist

0.03
0.000.00%

15min DelayTrading Mar 4 09:33 ET

0.00High0.00Low

BioCardia Stock Discussion

Jaguar8

Jul 17 06:01

NEWS

$BioCardia(BCDA.US)$
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
BioCardia, Inc. [Nasdaq: BCDA] has been granted U.S. Patent No. 12,036,371 for its Morph DNA multi-directional steerable catheter transseptal application. The patent, expiring in 2035, covers medical methods for transseptal access to the heart using steerable introducers based on BioCardia's Morph DNA technology. This innovation enhances shareholder...

TrendTrader

Jul 15 15:04

Over 4.7 has room to 5.3 and 5.7

$BioCardia(BCDA.US)$ Hehehe

Jaguar8

Jul 8 06:00

NEWS

$BioCardia(BCDA.US)$
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
CellProthera and BioCardia announced the successful completion of a collaborative Phase II trial of ProtheraCytes for treating acute myocardial infarction (AMI). The EXCELLENT Trial results showed that the transendocardial injection of ProtheraCytes, which are autologous, expanded CD34+ stem cells, in combination with standard care, helpe...

Trytosaveabit

Jun 12 06:41

Insider buy

$BioCardia(BCDA.US)$ Officer Altman Peter purchased 1,000 shares of common stock on Jun 10, 2024 at an average price of $3.36 for a total value of $3,360.

Stock Region

Jun 10 05:26

Therapeutics Company Announces U.S. Patent For Heart Therapy Treatment

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach.
BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, has announced a breakthrough in its technological advancements. The United States Patent Office has granted BioCardia...